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ABSTRACT
The b-lactamases produced by 14 non-duplicate
Klebsiella pneumoniae isolates and five Escherichia
coli isolates from urine samples obtained from
outpatients were characterised by isoelectric
focusing, substrate profile determination, PCR
and sequencing of blaSHV genes. Three E. coli A15
R+ transconjugants were identified as isolates that
produced SHV-5 b-lactamase. This report is the
first description of SHV-5 b-lactamase among
community isolates. Since the isolates showed
distinct pulsed-field gel electrophoresis patterns,
it was concluded that there was no clonal
spread of blaTEM and blaSHV genes, and that
dissemination of the blaTEM and blaSHV genes
was the result of exchange of plasmids among
different clones.
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Plasmid-encoded resistance to broad-spectrum
cephalosporins and aztreonam is becoming a
widespread problem in clinical medicine [1]. An
increase in the prevalence of extended-spectrum b-
lactamases (ESBLs) causing community-
acquired urinary tract infections has been observed
among children aged 0–6 years in Zenica-Doboj
Canton, Bosnia and Herzegovina [2,3]. The aim of
the present study was to characterise the ESBLs
found in Klebsiella pneumoniae and Escherichia coli
isolates from urinary tract infections in this region.
The Laboratory for Sanitary and Clinical Micro-
biology, Cantonal Public Health Institution,
Zenica, serves a population of 331 229 in the
Zenica-Doboj Canton of Bosnia-Herzegovina
(112 471 males and 218 758 females). Between
May 2004 and April 2005, 2059 enterobacterial
isolates were obtained consecutively from single
outpatient urine samples. Basic patient demogra-
phical data were recorded routinely for all urine
samples. Antibiotic susceptibility to 15 antimicro-
bial agents was tested initially by disk-diffusion
according to CLSI recommendations [4], with the
production of ESBLs being confirmed by double-
disk synergy tests [5]. Nineteen ESBL-producing
isolates were available for further testing. MICs of
a wide range of antibiotics were determined by a
two-fold microdilution test according to CLSI
recommendations [4].
Transfer of resistance to oxymino cephalospo-
rins was tested by conjugation (broth mating
method), with E. coli strain A15 R– (resistant to
rifampicin) as the recipient [6]. Crude bacterial
sonicates were subjected to isoelectric focusing on
polyacrylamide gels with a pH range of 3.5–10 [7].
b-Lactamases were detected by staining the gels
with nitrocefin (Oxoid, Basingstoke, UK). Refer-
ence strains producing TEM-1, TEM-2, SHV-1,
SHV-2, SHV-3, SHV-4, SHV-5 and CTX-M-15
were used as pI standards.
Specific blaESBL genes were detected by PCR
with primers specific for TEM, SHV and CTX-M
b-lactamases (Table 1). PCR conditions com-
prised 94C for 5 min, followed by 35 cycles of
95C for 1 min, 55C (68C for SHV [8]) for
1 min and 72C for 1 min. Reference strains
producing TEM-1, TEM-2, SHV-1, SHV-2, SHV-3,
SHV-4 and CTX-M-15 were used as positive
controls. The blaSHV genes of the three transcon-
jugants derived from the K. pneumoniae isolates
14213, 35117 and 35123 (see below) were se-
quenced using an ABI PRISM 377 Genetic
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Analyser (Applied Biosystems, Warrington, UK).
Using the primer pairs listed above, all ampli-
cons of the blaSHV genes spanned the entire open
reading frame.
Transconjugant plasmid DNA was extracted
by alkaline lysis [9], digested with EcoRI and
analysed by electrophoresis on agarose 0.8% w ⁄ v
gels. Pulsed-field gel electrophoresis of XbaI-
digested genomic DNA was performed using a
CHEF-DRII system (Bio-Rad, Hemel Hempstead,
UK) [10]. The images were processed using
GelCompar software (Applied Maths, Sint-Mar-
tens-Latem, Belgium), and a dendogram was
computed after band intensity correlation using
global alignment with 2% optimisation and clus-
tering using the unweighted pair-group method
with arithmetical averages (UPGMA).
The 2059 enteric bacterial isolates included
in the study comprised 68.1% E. coli, 23.7%
Klebsiella spp., 6.8% Proteus spp., 0.7% Citrobacter
spp. and 0.7% Enterobacter spp. ESBLs were
detected by double-disk synergy tests and an
eight-fold reduction in the ceftazidime MIC in the
presence of clavulanic acid (2 mg ⁄L) in 55 (2.7%)
isolates, of which 44 were Klebsiella spp., eight
were E. coli, and three were Enterobacter spp. ESBL
producers were isolated from 42.6% of children
aged £6 years. The prevalence of ESBL producers
from males was double that of isolates from
females (69.1% and 30.9%, respectively), resulting
in incidences of 8.7% and 1%, respectively.
The antibiotic susceptibilities of 19 selected
isolates are shown in Table 1. The addition of
clavulanic acid to ceftazidime reduced the MIC to
<2 mg ⁄L. Imipenem and meropenem remained
active (MICs <0.5 and <0.25 mg ⁄L, respectively).
Transfer of antibiotic resistance was achieved
for ten K. pneumoniae and three E. coli isolates
(Table 1). Resistance to non-b-lactam antibiotics
was co-transferred with cephalosporin resistance
in most cases.
E. coli isolates and their resulting transconju-
gants showed b-lactamase activity at a pI of 5.4,
corresponding to TEM-1, while K. pneumoniae
isolates and their resulting E. coli transconjugants
showed b-lactamase activity at a pI of 8.2, corres-
ponding to SHV-5. PCR detected blaSHV genes in
all K. pneumoniae isolates and their transconju-
gants, and blaTEM genes in all E. coli isolates. No
CTX-M b-lactamase producers were found.
Sequencing of blaSHV from three transconju-
gants (14213, 35117 and 35123) revealed two
mutations: at Ambler amino-acid position 238
(GGCﬁAGC, glycineﬁserine), typical for all SHV
ESBLs, and at Ambler amino-acid position 240
(GAGﬁAAG, glutamic acidﬁlysine), typical for
SHV-5. Based on sequencing data, enzymes from
all three tranconjugants were identified as SHV-5.
Table 1. Characterisation of b-lactamases and MICs for Klebsiella pneumoniae and Escherichia coli isolates producing
extended-spectrum b-lactamases
Isolate
Age
(years) M ⁄ F
PCR-
CTX-
Ma
PCR-
TEMb
pI
of
enzyme
Frequency
of
conjugation
Co-transferred
resistance
markers
PFGE
type
Antibiotic
AMX AMC CAZ CAZ ⁄CL CTX CRO FEP AMT IMI MEM GM NM TM
K. pneumoniae
14213 56 F – – 82 10)3 GM, NM, TM, T 1 ‡1024 64 ‡1024 1 32 64 32 ‡1024 0.12 0.06 32 32 64
35117 0 M – – 82 10)3 GM, NM, TM, T 2 ‡1024 16 128 0.25 8 16 32 256 0.06 0.06 16 32 128
35123 64 M – – 82 10)5 T, C 3 ‡1024 32 256 0.5 32 32 16 512 0.12 0.03 16 32 128
37464 01 F – – 82 10)6 T, C 4 ‡1024 32 128 0.12 8 8 32 512 0.06 0.03 64 16 64
110 48 M – – 82 10)4 T, C 5 ‡1024 8 64 0.12 32 64 8 128 0.03 £0.016 16 8 32
836 86 M – – 82 – 6 ‡1024 16 128 0.25 16 64 8 128 0.06 £0.016 64 16 32
3069 69 M – – 82 10)5 None 7 ‡1024 64 ‡1024 1 64 128 16 ‡1024 0.25 0.06 128 32 64
3075 74 F – – 8.2 10)4 GM, NM, TM, C 8 ‡1024 8 32 0.06 16 32 16 128 0.03 £0.016 16 4 16
4897 70 M – – 8.2 – 9 ‡1024 ‡128 >1024 2 32 64 64 >1024 0.12 £0.016 0.25 0.06 0.5
8329 0 F – – 8.2 10)6 GM, NM, TM, T, C 10 ‡1024 2 64 0.06 64 16 32 256 0.06 £0.016 4 1 8
16454 01 M – – 8.2 – 11 ‡1024 32 512 0.25 8 16 32 ‡1024 0.25 0.06 16 8 32
15822 01 M – – 8.2 10)6 GM, NM, TM, T, C 12 ‡1024 2 16 0.06 8 8 4 32 0.5 0.25 16 16 128
17178 0 M – – 8.2 – 13 ‡1024 ‡128 ‡1024 1 16 16 32 512 0.12 0.06 16 16 32
13086 0 M – – 8.2 10)3 GM, NM, TM, T 14 ‡1024 8 128 0.12 8 16 8 128 0.25 0.06 32 8 16
E. coli
32248 01 M – + 5.4 10)5 None 1 ‡1024 4 32 0.25 4 4 4 64 £0.016 £0.016 8 16 32
35955 72 M – + 5.4 10)3 GM, NM, AK, C 2 ‡1024 16 128 0.5 16 32 16 512 0.06 £0.016 32 32 64
16 73 M – + 5.4 – 3 ‡1024 4 32 0.12 8 16 8 32 £0.016 £0.016 64 32 128
83 68 M – + 5.4 – 4 ‡1024 8 128 0.25 32 64 16 256 £0.016 £0.016 128 32 64
15911 01 M – + 5.4 10)4 GM, NM, AK, C 5 ‡1024 16 64 0.12 2 16 4 128 0.12 0.06 16 8 16
M ⁄ F, male ⁄ female; PFGE, pulsed-field gel electrophoresis; AMX, amoxycillin; AMC, amoxycillin–clavulanate; CAZ, ceftazidime; CAZ ⁄CL, ceftazidime–clavulanate; CTX,
cefotaxime; CRO, ceftriaxone; FEP, cefepime; AMT, aztreonam; IMI, imipenem; MEM, meropenem; GM, gentamicin; NM, netilmycin, AK, amikacin; TM, tobramycin; C,
chloramphenicol; T, tetracycline.
aSequences of primers: 5¢-SCSATGTGCAGYACCAGTAA (MA1) and 5¢-CCGCRATATGRTTGGTGGTG (MA-2).
bSequences of primers: 5¢-CGCCGGGTTATTCTTATTTGTCGC (OT3-A) and 5¢-TCTTTCCGATGCCGCCGCCAGTCA (OT4-B).
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Plasmid analysis after digestion with EcoR1
showed that the transconjugants harboured plas-
mids with distinct fingerprinting patterns. The
K. pneumoniae and E. coli isolates also showed
distinct pulsed-field gel electrophoresis patterns
(Fig. 1).
The overall prevalence of ESBL-producing iso-
lates in the community (2.7%) found in this study
corresponds to the prevalence found in hospital
settings and private healthcare centres in other
reports [11]. The present study revealed a higher
prevalence of ESBL-producing isolates among
K. pneumoniae than among E. coli, which is in
contrast with previous studies, in which E. coli
was the most prevalent ESBL-producing species
isolated from outpatient samples [12]. This was
probably a result of the large proportion of
Klebsiella spp. isolated from community-acquired
urinary tract infections, as K. pneumoniae is
usually associated with hospital settings and
complicated community-acquired urinary tract
infections [12,13]. The median age of the patients
(35 years) was lower than that in previous stud-
ies, and the finding that male patients were
infected more frequently with ESBL-producing
strains than female patients is also in contrast to
previous reports [14,15].
Overall, the results indicate that microorgan-
isms carrying ESBL genes are present in patients
in the community in Bosnia and Herzagovina, as
well as in other countries [13,14,16]. Transmission
of ESBL producers from the hospital to the
community cannot be excluded, particularly since
there are reports of prolonged carriage of such
strains after hospitalisation [17]. Furthermore,
evidence of ESBL-producers in cattle, poultry,
dogs and cats suggests that food-producing ani-
mals and house pets might also act as a reservoir
in the community for the acquisition of such
organisms [18]. Misuse or overuse of antimicro-
bial drugs in Bosnia and Herzegovina, as well as
the migratory flux of regional populations, could
result in the emergence and selection of ESBL-
producers in the community [2,3].
In conclusion, this study showed that SHV-type
and TEM-type ESBLs predominated among com-
munity isolates of K. pneumoniae and E. coli,
respectively. This is in contrast to previous
reports that CTX-M-type b-lactamases are pre-
dominant among E. coli community isolates [19].
Both TEM- and SHV-type b-lactamases are usu-
ally limited to nosocomial isolates of Klebsiella
spp. [1,20]. This is the first report of the predom-
inance of SHV-5 among community isolates. Since
Fig. 1. Dendrograms obtained following pulsed-field gel electrophoresis (PFGE) of XbaI-digested genomic DNA from 19
extended-spectrum b-lactamase-producing isolates of (a) Escherichia coli and (b) Klebsiella pneumoniae.
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the isolates showed diverse pulsed-field gel elec-
trophoresis patterns, it was concluded that clonal
spread of blaTEM and blaSHV genes had not
occurred, and that dissemination of the blaTEM
and blaSHV genes was probably a result of genetic
exchange of plasmids among different clones.
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